HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Raises Price Target to $40
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and raises the price target from $36 to $40.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and raises the price target from $36 to $40.
